Published online Jan 26, 2025. doi: 10.4252/wjsc.v17.i1.97905
Revised: November 6, 2024
Accepted: January 2, 2025
Published online: January 26, 2025
Processing time: 221 Days and 17.3 Hours
Endometrial injury caused by repeated uterine procedures, infections, inflammation, or uterine artery dysfunction can deplete endometrial stem/progenitor cells and impair regeneration, thereby diminishing endometrial receptivity and evidently lowering the live birth, clinical pregnancy, and embryo implantation rates. Currently, safe and effective clinical treatment methods or gene-targeted therapies are unavailable, especially for severe endometrial injury. Umbilical cord mesenchymal stem cells and their extracellular vesicles are characterized by their simple collection, rapid proliferation, low immunogenicity, and tumorigenicity, along with their involvement in regulating angiogenesis, immune response, cell apoptosis and proliferation, inflammatory response, and fibrosis, Therefore, these cells and vesicles hold broad potential for application in endometrial repair. This article reviewed recent research on human umbilical cord mesenchymal stem cells as well as their extracellular vesicles in repairing endometrial injury.
Core Tip: This study explored the therapeutic potential of human umbilical cord mesenchymal stem cells (hucMSCs) as well as their extracellular vesicles in repairing endometrial injury. We demonstrated that hucMSCs promote endometrial regeneration through various mechanisms, such as cell proliferation, anti-fibrosis, angiogenesis, and immunomodulation. The findings highlighted the advantages of hucMSCs, including their low immunogenicity and ethical acceptability, making them a promising candidate for clinical applications. Our work addressed current challenges in hucMSC therapy, laying the groundwork for future standardized protocols and potentially offering new hope for females with endometrial dysfunction.